Skip to main content
SpringerLink
Log in

Mélanomes

  • Chapter
Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique

  • 472 Accesses

Abstrait

Le mélanome est une tumeur qui pose àl’heure actuelle un problème majeur de santé publique. En effet, il a été observé depuis plusieurs décennies une augmentation franche de son incidence, celle-ci doublant environ tous les 10 ans, et, actuellement, environ 6000 nouveaux cas sont dépistés en France chaque année.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Halna J.-M. Les mélanomes, in Incidence du cancer en France. Estimations régionales 1985-1995. Réseau français des registres du cancer.

    Google Scholar 

  2. Parkin DM, Whelan SL, Ferlay J et al, eds. Cancer incidence in five continents. Vol. VIII, no 55. Lyon: IARC Scientific Publications; 2002.

    Google Scholar 

  3. Rager EL, Bridgeford EP, Ollila DW. Cutaneous melanoma: update on prevention, screening, diagnosis, and treatment. Am Fam Physician 2005; 72:269–276.

    PubMed  Google Scholar 

  4. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25:459–463.

    Article  PubMed  CAS  Google Scholar 

  5. Jones WO, Harman CR, Ng AK, Shaw JH. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg 1999; 23:732–735.

    Article  PubMed  CAS  Google Scholar 

  6. Lipsker DM, Hedelon G, Heid E et at Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999; 135:1451–1456.

    Article  PubMed  CAS  Google Scholar 

  7. Melia J, Frost T, Graham-Brown R et al. Problems with registration of cutaneous malignant melanoma in England. Br J Cancer 1995; 72: 224–228.

    PubMed  CAS  Google Scholar 

  8. Koh NK, Geller A, Miller DR et al. Underreporting of cutaneous melanoma in cancer registries nationwide. J Am Acad dermatol 1992; 27:1035–1036.

    Article  PubMed  CAS  Google Scholar 

  9. Severi G, Giles GG, Robertson C et al. Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer 2000; 82:1887–1891.

    Article  PubMed  CAS  Google Scholar 

  10. Florez A, Cruces M. Melanoma epidemic: true or false ? Int J Dermatol 2004; 43:405–407.

    Article  PubMed  Google Scholar 

  11. La Vecchia C, Lucchini F, Negri E et al. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer 1999; 81:62–66.

    Article  Google Scholar 

  12. Brochez L, Naevaert JM. Understanding the trends in melanoma incidence and mortality: where do we stand ? Eur J Dermatol 2000; 10:71–76.

    PubMed  CAS  Google Scholar 

  13. Ortiz CA, Goodwind JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit 2005; 11: RA163–172.

    PubMed  Google Scholar 

  14. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Recent developments in epidemiology. Arch Dermatol 1996; 132:444–450.

    Article  PubMed  CAS  Google Scholar 

  15. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001; 12: 69–82.

    Article  PubMed  CAS  Google Scholar 

  16. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923–936.

    Article  PubMed  CAS  Google Scholar 

  17. Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol 2004; 51:803–808.

    Article  PubMed  Google Scholar 

  18. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8:23–26.

    Article  PubMed  CAS  Google Scholar 

  19. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15–21.

    Article  PubMed  CAS  Google Scholar 

  20. Zuo L, Weger J, Yang Q et al Germline mutations in the pl6INK4a binding domain of CDK4 in familial melanoma. Wat Genet 1996; 12:97–99.

    Article  CAS  Google Scholar 

  21. Valverde P, Healy E, Sikking S et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5:1663–1666.

    Article  PubMed  CAS  Google Scholar 

  22. Palmer JS, Duffy DL, Box NF et al. Melano-cortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66:176–186.

    Article  PubMed  CAS  Google Scholar 

  23. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: L Common and atypical naevi. Eur J Cancer 2005; 41:28–44.

    Article  PubMed  Google Scholar 

  24. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41:45–60.

    Article  PubMed  Google Scholar 

  25. Gandini S, Sera F, Cattaruzza MS et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040–2059.

    Article  PubMed  Google Scholar 

  26. Siskind V, Whiteman DC, Aitken JF. An analysis of risk factors for cutaneous melanoma by anatomical site (Australia). Cancer Causes Control 2005; 16:193–199.

    Article  PubMed  Google Scholar 

  27. Grob JJ, Gouvernet J, Aymard D. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66:387–395.

    Article  PubMed  CAS  Google Scholar 

  28. Hollenbeak CS, Todd MM, Billingsley EM et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104: 1962–1967.

    Article  PubMed  Google Scholar 

  29. Egan CL, Oliveria SA, Elenitsas R et al. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: a follow-up study of 46 patients. J Am Acad Dermatol 1998; 39:923–932.

    Article  PubMed  CAS  Google Scholar 

  30. Sahin S, Levin L, Kopf AW. Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol 1998; 39:428–433.

    Article  PubMed  CAS  Google Scholar 

  31. Tannous ZS, Mihm MC Jr, Sober AJ et al. Congenital melanocytic naevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad dermatol 2005; 52:197–203.

    Article  PubMed  Google Scholar 

  32. Bett J. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. J Am Acad Dermatol 2005; 52: 793–797.

    Article  PubMed  Google Scholar 

  33. Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70:1917–1927.

    Article  PubMed  Google Scholar 

  34. Delaunay M. Diagnosis and follow up of cutaneous melanoma. Rev Prat 2004; 54:1193–1201.

    PubMed  Google Scholar 

  35. Healsmith MF, Bourke JF, Osborne JF et al. An evaluation of the revised seven-point checklist for the early diagnosis of cutaneous malignant melanoma. Br J Dermatol 1994; 130:48–50.

    Article  PubMed  CAS  Google Scholar 

  36. Wolf IH, Smolle J, Soyer HR Sensitivity in the clinical diagnosis of malignant melanoma. Melanom Res 1998; 8:425–429.

    Article  CAS  Google Scholar 

  37. Carli P, De Giorgi V, Crocetti E et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the «dermoscopy era»: a retrospective study 1997–2001. Br J Dermatol 2004; 150:687–692.

    Article  PubMed  CAS  Google Scholar 

  38. Carli P, De Giorgi V, Palli D et al. Preoperative assessment of melanoma thickness by ABCD score of dermatoscopy. J Am Acad Dermatol 2000; 43:459–466.

    Article  PubMed  CAS  Google Scholar 

  39. Braun RP, Rabinovitz H, Oliviero M. De-matoscopie des lésions pigmentées. Ann Dermatol Venereal 2002; 129:187–202.

    CAS  Google Scholar 

  40. Soong SJ, Harrison RA, McCarthy WH et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67:228–233.

    Article  PubMed  CAS  Google Scholar 

  41. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992; 8:400–414.

    Article  PubMed  CAS  Google Scholar 

  42. Urist MM, Balch CM, Soong SJ et al. 42. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 1984; 200: 769–775.

    Article  PubMed  CAS  Google Scholar 

  43. Recommandations pour la pratique clinique: Standards, Options et Recommandations 2005 pour la prise en charge des patients adultes atteints d’un mélanome cutané MO. Ann Dermatol Venereol 2005; 132:10S13.

    Google Scholar 

  44. Lens MB, Dawes M, Goodacre T et al. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Arch Surg 2002; 137:1101–1015.

    Article  PubMed  Google Scholar 

  45. Haigh PI, Di Fronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003; 46:419–426.

    PubMed  Google Scholar 

  46. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126:438–441.

    PubMed  CAS  Google Scholar 

  47. Cohn-Cedermark G, Rutqvist LE et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2,0 mm. Cancer 2000; 89:1495–1501.

    Article  PubMed  CAS  Google Scholar 

  48. Balch CM, Soong SJ, Smith T et al. Investigators from the Intergroup Melanoma Surgical Trial. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8:101–108.

    PubMed  CAS  Google Scholar 

  49. Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–399.

    Google Scholar 

  50. Bleicher RJ, Essner R, Foshag LJ et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003; 21: 1326–1331.

    Article  PubMed  Google Scholar 

  51. Blumenthal R, Bank A, Brand CU et al. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg 2002; 8: 209–214.

    Article  PubMed  CAS  Google Scholar 

  52. Chao C, Wong SL, Ross MI et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184:520–524.

    Article  PubMed  Google Scholar 

  53. Doting MH, Hoekstra HJ, Plukker JT et al. Is sentinel node biopsy beneficial in melanoma patients ? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol 2002; 28: 673–678.

    Article  PubMed  CAS  Google Scholar 

  54. Essner R, Chung MH, Bleicher R et al. Prognostic implications of thick (> or = 4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann of Surg Oncol 2002; 9:754–761.

    Google Scholar 

  55. Gadd MA, Cosimi AB, Yu J et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134:381–387.

    Article  PubMed  CAS  Google Scholar 

  56. Jansen L, Nieweg OE, Peterse JL et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87:484–489.

    Article  PubMed  CAS  Google Scholar 

  57. Liszkay G, Peley G, Sinkovics I et al. Clinical significance of sentinel lymph node involvement in malignant melanoma. Pathol Oncol Res 2003; 9:184–187.

    Article  PubMed  Google Scholar 

  58. Statius Muller MG, van Leeuwen PA, de Lange et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer 2001; 91:2401–2408.

    Article  PubMed  CAS  Google Scholar 

  59. Vuylsteke RJ, van Leeuwen PA, Statius Muller MG et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21:1057–1065.

    Article  PubMed  CAS  Google Scholar 

  60. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1. Lancet 1998; 351:1905–1910.

    Google Scholar 

  61. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998; 16:1425–1429.

    PubMed  CAS  Google Scholar 

  62. Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444–2458.

    PubMed  CAS  Google Scholar 

  63. Cascinelli N, Belli F, MacKie RM et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node métastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866–869.

    Google Scholar 

  64. Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M. versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40:390–402.

    Article  PubMed  CAS  Google Scholar 

  65. Lens MB, Dawes M, Goodacre T et al. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 2002; 137:458–461.

    Article  PubMed  Google Scholar 

  66. Dreno B, Nguyen JM, Khammari A et al. Randomized trial of adoptive transfer of melanoma tumor infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51:539–546.

    Article  PubMed  CAS  Google Scholar 

  67. Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. Bio drugs 2005; 19:247–260.

    CAS  Google Scholar 

  68. Jotereau F, Labarriere N, Gervois N et al. L’immunothérapie passive du melanome. Bull Cancer 2003; 90:583–586.

    PubMed  Google Scholar 

  69. Van Baren N, Bonnet MC, Dréno B et al. Tumoral and immunological response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23:9008–9021.

    Article  PubMed  CAS  Google Scholar 

  70. Kruit WHJ, Van Ojic HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596–604.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Dermatologie, Place Alexis-Ricordeau, 44093, Nantes CEDEX 1

    Brigitte Dreno (Professeur)

Authors
  1. Gaëlle Querem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brigitte Dreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Querem, G., Dreno, B. (2009). Mélanomes. In: Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique. Springer, Paris. https://doi.org/10.1007/978-2-287-72092-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72092-5_16

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72091-8

  • Online ISBN: 978-2-287-72092-5

Publish with us

Policies and ethics

Search

Navigation